Investor Announcement
April 03, 2020 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, April 03, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, has learnt that buy recommendations and letters are being...
Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs
March 30, 2020 06:00 ET
|
Revive Therapeutics Ltd.
TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for...
Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19
March 25, 2020 17:46 ET
|
Revive Therapeutics Ltd.
TORONTO, March 25, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for rare...
Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19
March 24, 2020 10:04 ET
|
Revive Therapeutics Ltd.
TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that Dr. David Boulware, MD, MPH,...
Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19
March 20, 2020 06:00 ET
|
Revive Therapeutics Ltd.
TORONTO, March 20, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug...
Revive Therapeutics Announces Closing of Brokered Private Placement
March 18, 2020 13:18 ET
|
Revive Therapeutics Ltd.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, March 18, 2020 (GLOBE...
Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.
March 05, 2020 14:35 ET
|
Revive Therapeutics Ltd.
TORONTO, March 05, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel psychedelic and...
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
February 18, 2020 08:41 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and...
Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.
February 12, 2020 09:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the...
Revive Therapeutics Announces Brokered Private Placement of up to $2 million
February 11, 2020 17:00 ET
|
Revive Therapeutics Ltd.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE)...